Evolus (EOLS) Expected to Announce Earnings on Wednesday

Evolus (NASDAQ:EOLS) is projected to post its Q1 2025 quarterly earnings results after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $73.06 million for the quarter.

Evolus Price Performance

Shares of EOLS stock opened at $12.01 on Tuesday. The stock has a market capitalization of $774.30 million, a price-to-earnings ratio of -13.20 and a beta of 1.11. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. Evolus has a twelve month low of $8.67 and a twelve month high of $17.82. The stock has a fifty day simple moving average of $11.94 and a two-hundred day simple moving average of $12.68.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on EOLS. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Thursday, April 10th. Barclays increased their price objective on shares of Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. BTIG Research began coverage on shares of Evolus in a research report on Thursday, April 17th. They set a “buy” rating and a $21.00 target price on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research note on Wednesday, April 9th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $23.75.

Insiders Place Their Bets

In other news, insider David Moatazedi sold 6,251 shares of the business’s stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the transaction, the insider now directly owns 508,619 shares of the company’s stock, valued at approximately $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Rui Avelar sold 27,904 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the completion of the transaction, the insider now owns 362,467 shares in the company, valued at approximately $4,806,312.42. The trade was a 7.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 60,575 shares of company stock valued at $794,369 over the last ninety days. Company insiders own 6.10% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.